Capital Advisors Ltd’s TG Therapeutics TGTX Stock Holding History

Capital Advisors Ltd’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6K	Buy	106 +30	+39%	+$1.23K	﹤0.01%	949
2026 Q1	$3K	Sell	76 -124	-62%	-$3.69K	﹤0.01%	1059
2025 Q4	$6K	Buy	200 +124	+163%	+$4.05K	﹤0.01%	919
2025 Q3	$3K	Hold	76	–	–	﹤0.01%	1028
2025 Q2	$3K	Hold	76	–	–	﹤0.01%	1022
2025 Q1	$3K	Hold	76	–	–	﹤0.01%	1014
2024 Q4	$2K	Hold	76	–	–	﹤0.01%	1113
2024 Q3	$2K	Hold	76	–	–	﹤0.01%	1107
2024 Q2	$1K	Hold	76	–	–	﹤0.01%	1297
2024 Q1	$1K	Hold	76	–	–	﹤0.01%	1274
2023 Q4	$1K	Hold	76	–	–	﹤0.01%	1226
2023 Q3	$1K	Hold	76	–	–	﹤0.01%	1218
2023 Q2	$2K	Hold	76	–	–	﹤0.01%	1050
2023 Q1	$1K	Hold	76	–	–	﹤0.01%	1118
2022 Q4	$1K	Buy	+76	New	+$552	﹤0.01%	1097
2022 Q2	–	Sell	-17	Closed	–	–	1316
2022 Q1	$0	Buy	+17	New	+$197	﹤0.01%	1196

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Capital Advisors Ltd's TGTX Position: Q2 2026 in Review

Capital Advisors Ltd increased its TG Therapeutics (TGTX) stake by 39% in Q2 2026, buying an estimated $1.23K and bringing the position to 106 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

Capital Advisors Ltd first reported a position in TGTX in Q1 2022 and has held it in 16 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Capital Advisors Ltd held 106 shares of TG Therapeutics worth $6K as of Q2 2026.
Capital Advisors Ltd bought 30 TG Therapeutics shares in Q2 2026, an estimated $1.23K.
TG Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #949 holding.
Capital Advisors Ltd first reported a position in TG Therapeutics in Q1 2022 and has held it in 16 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.